AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXThe company said its net CF product revenues rose to $2.7 billion in Q1 2024, up from $2.4 billion in Q1 2023. It cited higher TRIKAFTA/KAFTRIO prescriptions in ex-U.S. markets and TRIKAFTA performance in the U.S. as the drivers of the increase.
Key points
AI summaryThe company said its net CF product revenues rose to $2.7 billion in Q1 2024, up from $2.4 billion in Q1 2023. It cited higher TRIKAFTA/KAFTRIO prescriptions in ex-U.S. markets and TRIKAFTA performance in the U.S. as the drivers of the increase.
Vertex said operating cash flow rose to $1.3 billion in Q1 2024, up from $899.9 million in Q1 2023. Cash, cash equivalents and marketable securities stood at $14.6 billion as of March 31, 2024, up from $13.7 billion as of December 31, 2023.
In April 2024, Vertex said it entered into a merger agreement to acquire all outstanding shares of Alpine Immune Sciences for approximately $4.9 billion and commenced a tender offer at $65 per share in cash. The company said it expects the transaction to close in Q2 2024 and plans to fund it with cash and cash equivalents on hand.
Vertex said its cost of sales rose to 13% of net product revenues in Q1 2024, compared with 11% in Q1 2023, and cited cost of sales associated with CASGEVY as the reason. The company said its selling, general and administrative expenses increased 42% compared with Q1 2023.
Key figures
Quarter ended March 31, 2024
- Revenue
- $2.7B
- Operating income
- $1.1B
- Net income
- $1.1B
- EPS
- $4.21
- Operating cash flow
- $1.3B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q1 2024 CF Product Revenues, Net $2.7 billion
The company said its net CF product revenues rose to $2.7 billion in Q1 2024, up from $2.4 billion in Q1 2023. It cited higher TRIKAFTA/KAFTRIO prescriptions in ex-U.S. markets and TRIKAFTA performance in the U.S. as the drivers of the increase.
Source · Based on the MD&A text of the filing
Operating Cash Flow and Cash Balance
Vertex said operating cash flow rose to $1.3 billion in Q1 2024, up from $899.9 million in Q1 2023. Cash, cash equivalents and marketable securities stood at $14.6 billion as of March 31, 2024, up from $13.7 billion as of December 31, 2023.
Source · Based on the MD&A text of the filing
Agreement to Acquire Alpine Immune Sciences
In April 2024, Vertex said it entered into a merger agreement to acquire all outstanding shares of Alpine Immune Sciences for approximately $4.9 billion and commenced a tender offer at $65 per share in cash. The company said it expects the transaction to close in Q2 2024 and plans to fund it with cash and cash equivalents on hand.
Source · Based on the MD&A text of the filing
Cost of Sales Ratio and SG&A Growth
Vertex said its cost of sales rose to 13% of net product revenues in Q1 2024, compared with 11% in Q1 2023, and cited cost of sales associated with CASGEVY as the reason. The company said its selling, general and administrative expenses increased 42% compared with Q1 2023.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…